Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | FPR2 | P25090 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15992851 | 0.87 | SCN9A (0.69) | MAPTNPSR1SCN9ALMNAFPR2 | |
| SCHEMBL11351938 | 0.82 | MAPT (0.69) | MAPTNPSR1LMNATHRBRAB9A | |
| SCHEMBL4728325 | 0.81 | KDM4E (0.62) | MAPTNPSR1LMNATHRBRAB9A | |
| SCHEMBL19072372 | 0.79 | SCN9A (0.71) | SCN9ALMNAFPR2 | |
| SCHEMBL30006227 | 0.77 | LMNA (0.53) | MAPTNPSR1SCN9ALMNATHRB | |
| SCHEMBL27638920 | 0.77 | NPC1 (0.66) | MAPTLMNATHRBRAB9A | |
| SCHEMBL22607453 | 0.75 | SCN9A (0.72) | SCN9AFPR2 | |
| SCHEMBL906222 | 0.75 | LMNA (0.63) | MAPTNPSR1SCN9ALMNATHRB | |
| SCHEMBL11383589 | 0.75 | LIPE (0.65) | MAPTNPSR1LMNATHRBRAB9A | |
| SCHEMBL21652204 | 0.75 | RAB9A (0.67) | MAPTNPSR1LMNATHRBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1037886-B1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2003-05-02 | — | — | EP | claimed |
| US-6150362-A | ADMINISTERING 1,3,5-SUBSTITUTED TRIAZINE COMPOUNDS TO THE PATIENT SUFFERING FROM ANGIOGENIC DISEASES | ABBVIE INC. | 2000-11-21 | — | — | US | claimed |
| EP-1037886-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2000-09-27 | — | — | EP | claimed |
| WO-1999031088-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | claimed |
| EP-1037886-B1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6288228-B1 | DIAMINOTRIAZINE DERIVATIVES | ABBOTT LABORATORIES | 2001-09-11 | — | — | US | disclosed |
| US-6150362-A | ADMINISTERING 1,3,5-SUBSTITUTED TRIAZINE COMPOUNDS TO THE PATIENT SUFFERING FROM ANGIOGENIC DISEASES | ABBVIE INC. | 2000-11-21 | — | — | US | disclosed |
| EP-1037886-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999031088-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | disclosed |